Carl Dambkowski Sells 105,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the completion of the transaction, the director owned 73,743 shares of the company’s stock, valued at $4,348,624.71. This trade represents a 58.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oruka Therapeutics Trading Up 3.3%

NASDAQ ORKA traded up $1.92 during trading hours on Friday, reaching $60.61. 928,774 shares of the company’s stock were exchanged, compared to its average volume of 1,066,667. The stock has a market cap of $3.66 billion, a PE ratio of -31.24 and a beta of -0.20. Oruka Therapeutics, Inc. has a one year low of $10.64 and a one year high of $91.00. The firm has a fifty day moving average of $57.20 and a 200-day moving average of $40.29.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.04. As a group, research analysts forecast that Oruka Therapeutics, Inc. will post -2.05 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ORKA shares. BTIG Research reaffirmed a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a report on Thursday, May 14th. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a research report on Monday, April 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and set a $120.00 target price on shares of Oruka Therapeutics in a research report on Monday. Finally, Barclays increased their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Oruka Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $120.80.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds have recently added to or reduced their stakes in ORKA. Legal & General Group Plc bought a new stake in Oruka Therapeutics during the 2nd quarter worth about $28,000. BNP Paribas Financial Markets boosted its stake in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after purchasing an additional 2,306 shares during the last quarter. Royal Bank of Canada grew its position in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics during the 4th quarter worth approximately $37,000. Finally, PNC Financial Services Group Inc. bought a new stake in shares of Oruka Therapeutics during the third quarter worth approximately $39,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.